CLYM
Price
$10.25
Change
-$0.08 (-0.77%)
Updated
Oct 30 closing price
Capitalization
588.72M
5 days until earnings call
Intraday BUY SELL Signals
IMVT
Price
$29.17
Change
-$0.47 (-1.59%)
Updated
Oct 30 closing price
Capitalization
6.03B
9 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLYM vs IMVT

CLYM vs IMVT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CLYM vs. IMVT commentary
Oct 31, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLYM is a Buy and IMVT is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CLYM with price predictions
Oct 30, 2026

CLYM in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 26, 2026

CLYM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 38 cases where CLYM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLYM's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 70 cases where CLYM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on CLYM as a result. In 99 of 127 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for CLYM just turned positive on October 20, 2026. Looking at past instances where CLYM's MACD turned positive, the stock continued to rise in 46 of 58 cases over the following month. The odds of a continued upward trend are 79%.

Following a +7.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLYM advanced for three days, in 196 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLYM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for CLYM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.458) is normal, around the industry mean (3.154). P/E Ratio (-12.500) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CLYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for IMVT with price predictions
Oct 30, 2026

IMVT's RSI Indicator recovers from oversold territory

The RSI Oscillator for IMVT moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on IMVT as a result. In 77 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

Following a +2.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 204 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

IMVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.193) is normal, around the industry mean (3.154). P/E Ratio (-10.381) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
IMVT: Fundamental Ratings
IMVT
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
59
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
19
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CLYMIMVT
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 31, 2026
Stock price -- (CLYM: $10.25 vs. IMVT: $29.17)
Brand notoriety: CLYM and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLYM: 45% vs. IMVT: 83%
Market capitalization -- CLYM: $588.72M vs. IMVT: $6.03B
CLYM [@Biotechnology] is valued at $588.72M. IMVT’s [@Biotechnology] market capitalization is $6.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $141.65B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLYM’s FA Score shows that 2 FA rating(s) are green while IMVT’s FA Score has 1 green FA rating(s).

  • CLYM’s FA Score: 2 green, 3 red.
  • IMVT’s FA Score: 1 green, 4 red.
According to our system of comparison, CLYM is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLYM’s TA Score shows that 6 TA indicator(s) are bullish while IMVT’s TA Score has 5 bullish TA indicator(s).

  • CLYM’s TA Score: 6 bullish, 2 bearish.
  • IMVT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CLYM is a better buy in the short-term than IMVT.

Price Growth

CLYM (@Biotechnology) experienced а +0.59% price change this week, while IMVT (@Biotechnology) price change was +2.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.

Reported Earning Dates

CLYM is expected to report earnings on Nov 05, 2026.

IMVT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CLYM
Daily Signal:
Gain/Loss:
IMVT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CLYM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLYM has been loosely correlated with KYTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYM jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLYM
1D Price
Change %
CLYM100%
-0.77%
KYTX - CLYM
43%
Loosely correlated
-3.08%
IMNM - CLYM
42%
Loosely correlated
-0.44%
FDMT - CLYM
40%
Loosely correlated
-6.89%
LXEO - CLYM
40%
Loosely correlated
+2.61%
IMVT - CLYM
38%
Loosely correlated
-1.59%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-1.59%
ROIV - IMVT
63%
Loosely correlated
-1.63%
KURA - IMVT
52%
Loosely correlated
-2.84%
LXEO - IMVT
47%
Loosely correlated
+2.61%
NAMS - IMVT
46%
Loosely correlated
-3.37%
SYRE - IMVT
45%
Loosely correlated
-2.43%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MICC19.871.00
+5.30%
The Magnum Ice Cream Company NV
LSE4.320.17
+4.10%
Leishen Energy Holding Co Ltd
LXFR17.23-0.04
-0.23%
Luxfer Holdings PLC
UCTT49.71-4.99
-9.12%
Ultra Clean Holdings
BRTX1.42-0.16
-10.13%
BioRestorative Therapies Inc